The cancer biomarkers market is set to reach an impressive USD 42.0 billion by 2029, up from USD 24.5 billion in 2024, with a compound annual growth rate (CAGR) of 11.3%. This significant growth is fueled by rising cancer incidence, increased awareness of early diagnosis, and substantial investments in research and development.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202
Overview of Market Segments
Profiling Technology: Omics Leads the Way
The market is categorized by profiling technologies into omics and imaging. Omics technology, encompassing genomics, proteomics, and metabolomics, led the market in 2023 due to its high throughput and precision in identifying and diagnosing cancer biomarkers.
Cancer Types: Focus on Breast Cancer
By cancer type, the breast cancer segment dominated the market in 2023, driven by the increasing global incidence of breast cancer and the growing need for early diagnosis and prevention.
Products: Instruments at the Forefront
The product segment includes instruments, consumables, and bioinformatics software. Instruments held the largest market share in 2023, driven by the continuous demand for accurate cancer detection and technological advancements.
Applications: Diagnostics Take the Lead
In 2023, diagnostics led the market by application. The rise in cancer incidence and advancements in diagnostic tests have propelled this segment’s growth. Other application areas include risk assessment, prognostics, and research & development.
Regional Insights
North America: A Major Hub
North America held the largest share of the cancer biomarkers market in 2023, supported by a high prevalence of cancer, strong research initiatives, technological advancements, and extensive use of biomarkers in drug discovery.
Key Market Drivers
Several factors are driving market growth:
- Increasing Cancer Incidence: The global rise in cancer cases is a primary driver.
- Early Diagnosis Awareness: Increased awareness and initiatives for early cancer diagnosis are boosting market growth.
- R&D Investments: Significant investments in research and development for new cancer biomarkers are enhancing the market.
- Technological Advancements: Continuous technological improvements enhance the effectiveness and accuracy of cancer biomarker tests.
Emerging Markets: Opportunities in Asia
Countries like China, Japan, and India are becoming attractive markets for cancer biomarker companies due to their improving healthcare infrastructure and growing awareness of early cancer detection, presenting significant growth opportunities.
Major Players in the Market
Leading companies include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Thermo Fisher Scientific, Inc. (US)
- QIAGEN N.V. (Netherlands)
- Illumina, Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
- Abbott Laboratories (US)
- bioMérieux SA (US)
- Becton, Dickinson and Company (US)
- Merck Millipore (US)
- Agilent Technologies (US)
- Myriad Genetics, Inc. (US)
- Sysmex Corporation (Japan)
- Hologic, Inc. (US)
- Quest Diagnostics (US)
- Centogene N.V. (Germany)
Get Free Sample Pages: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202
Conclusion
The cancer biomarkers industry is poised for robust growth, driven by technological advancements, increasing cancer incidence, and substantial investments in research and development. As the market expands, particularly in developing regions, the role of cancer biomarkers in diagnosis, drug discovery, and treatment will become increasingly critical.
Related News:
https://www.prnewswire.com/news-releases/cancer-biomarkers-market-worth-42-0-billion–marketsandmarkets-302129875.html
https://www.marketwatch.com/press-release/cancer-biomarkers-market-worth-42-0-billion-marketsandmarkets-tm-e42d5a5f
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
